Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Comment by MrMugsyon Jan 07, 2021 9:13am
182 Views
Post# 32240757

RE:RE:New Hire

RE:RE:New Hire
Forestview wrote: Not sure if this will impact the stock much, but another step in the right direction, I suppose.  Looks like AskBio sold it's cell and gene theraphy platform, for $2B upfront, and an additional $2B in milestone success based incentives.  They're vague on what those incentives were (or at least I couldn't find them), and since this happened in Oct 2020, no idea if any have been achieved.

What's the group's thoughts on what a potential acquisition would look like for ATE?  Would it be a combo cash and incentive deal, given that some of their IP hasn't gone through the drug development phases?  Ideally, I think we'd all like to have cash and be done with it, but what's the chances of that?  


Yes - step in the right direction.  Means things are heating up (to use Dan's words).
Should be positive for the share price ... in combination with a few other initiatives as we get ready for Phase 3.
I still only assume 3-4 partners for OTENA.
Anything more than that (like a buyout of the business) would be a bonus and it would net us a few billion dollars.
Just my opinion.
<< Previous
Bullboard Posts
Next >>